Literature DB >> 18309362

NIH consensus development statement on hydroxyurea treatment for sickle cell disease.

Otis W Brawley, Llewellyn J Cornelius, Linda R Edwards, Vanessa Northington Gamble, Bettye L Green, Charles E Inturrisi, Andra H James, Danielle Laraque, Magda H Mendez, Carolyn J Montoya, Brad H Pollock, Lawrence Robinson, Aaron P Scholnik, Melissa Schori.   

Abstract

National Institutes of Health consensus and state-of-the-science statements are prepared by independent panels of health professionals and public representatives on the basis of (1) the results of a systematic literature review prepared under contract with the Agency for Healthcare Research and Quality (AHRQ), (2) presentations by investigators working in areas relevant to the conference questions during a 2-day public session, (3) questions and statements from conference attendees during open discussion periods that are part of the public session, and (4) closed deliberations by the panel during the remainder of the second day and morning of the third. This statement is an independent report of the panel and is not a policy statement of the NIH or the U.S. Government.The statement reflects the panel's assessment of medical knowledge available at the time the statement was written. Thus, it provides a "snapshot in time" of the state of knowledge on the conference topic. When reading the statement, keep in mind that new knowledge is inevitably accumulating through medical research.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18309362

Source DB:  PubMed          Journal:  NIH Consens State Sci Statements        ISSN: 1553-0779


  10 in total

1.  The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients.

Authors:  Wally R Smith; Samir K Ballas; William F McCarthy; Robert L Bauserman; Paul S Swerdlow; Martin H Steinberg; Myron A Waclawiw
Journal:  Pain Med       Date:  2011-04-11       Impact factor: 3.750

2.  Differential modulation of adhesion molecule expression by hydroxycarbamide in human endothelial cells from the micro- and macrocirculation: potential implications in sickle cell disease vasoocclusive events.

Authors:  Sandrine Laurance; Pauline Lansiaux; François-Xavier Pellay; Michelle Hauchecorne; Arndt Benecke; Jacques Elion; Claudine Lapoumeroulie
Journal:  Haematologica       Date:  2011-01-12       Impact factor: 9.941

3.  Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study.

Authors:  Jeffrey D Lebensburger; Scott T Miller; Thomas H Howard; James F Casella; R Clark Brown; Ming Lu; Rathi V Iyer; Sharada Sarnaik; Zora R Rogers; Winfred C Wang
Journal:  Pediatr Blood Cancer       Date:  2011-12-20       Impact factor: 3.167

4.  Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease.

Authors:  Carlton Haywood; Mary Catherine Beach; Shawn Bediako; C Patrick Carroll; Lakshmi Lattimer; Dasheema Jarrett; Sophie Lanzkron
Journal:  Am J Hematol       Date:  2011-01       Impact factor: 10.047

5.  Mortality rates and age at death from sickle cell disease: U.S., 1979-2005.

Authors:  Sophie Lanzkron; C Patrick Carroll; Carlton Haywood
Journal:  Public Health Rep       Date:  2013 Mar-Apr       Impact factor: 2.792

Review 6.  Sickle cell nephropathy: an update on pathophysiology, diagnosis, and treatment.

Authors:  Essa Hariri; Anthony Mansour; Andrew El Alam; Yazan Daaboul; Serge Korjian; Sola Aoun Bahous
Journal:  Int Urol Nephrol       Date:  2018-01-30       Impact factor: 2.370

7.  Monomethylfumarate induces γ-globin expression and fetal hemoglobin production in cultured human retinal pigment epithelial (RPE) and erythroid cells, and in intact retina.

Authors:  Wanwisa Promsote; Levi Makala; Biaoru Li; Sylvia B Smith; Nagendra Singh; Vadivel Ganapathy; Betty S Pace; Pamela M Martin
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-13       Impact factor: 4.799

Review 8.  Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries.

Authors:  Mercy Mulaku; Newton Opiyo; Jamlick Karumbi; Grace Kitonyi; Grace Thoithi; Mike English
Journal:  Arch Dis Child       Date:  2013-08-30       Impact factor: 3.791

9.  Comparative Effectiveness of a Web-Based Patient Decision Aid for Therapeutic Options for Sickle Cell Disease: Randomized Controlled Trial.

Authors:  Lakshmanan Krishnamurti; Diana Ross; Cynthia Sinha; Traci Leong; Namita Bakshi; Nonita Mittal; Divya Veludhandi; Anh-Phuong Pham; Alankrita Taneja; Kamesh Gupta; Julum Nwanze; Andrea Marie Matthews; Saumya Joshi; Veronica Vazquez Olivieri; Santhi Arjunan; Ifechi Okonkwo; Ines Lukombo; Peter Lane; Nitya Bakshi; George Loewenstein
Journal:  J Med Internet Res       Date:  2019-12-04       Impact factor: 5.428

10.  Inflammatory Dendritic Cells Contribute to Regulate the Immune Response in Sickle Cell Disease.

Authors:  Renata Sesti-Costa; Marina Dorigatti Borges; Carolina Lanaro; Dulcinéia Martins de Albuquerque; Sara Terezinha Olalla Saad; Fernando Ferreira Costa
Journal:  Front Immunol       Date:  2021-02-04       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.